Review Highlights Laser Treatment of Nonmelanoma Skin Cancer

TOPLINE:

Published recordsdata on laser medicine of nonmelanoma pores and skin cancer (NMSC) is encouraging, even if the treatment is not yet authorized by the US Food and Drug Administration (FDA) for this use.

METHODOLOGY:

• Using MEDLINE, the Cochrane Library, and www.clinicaltrials.gov, researchers systematically reviewed 50 queer published articles that evaluated the position of laser treatment for NMSC.
• Of the 50 compare, 37 centered on lasers for the medicine of basal cell carcinoma (BCC), 10 on lasers for the medicine of squamous cell carcinoma (SCC), and three on the medicine of both tumor kinds.
• The prognosis became restricted to investigate published in English from the first recordsdata on hand by draw of Would possibly well 1, 2023.

TAKEAWAY:

• Data became strongest for the utilization of lasers for treating BCC, particularly pulsed dye lasers (PDL). Of 11 queer compare on PDL as monotherapy for managing BCCs, clearance rates ranged from 14.3% to 90.0%.
• For SCCs, 13 compare had been identified that evaluated the utilization of lasers on my own or in conjunction with PDL for treating SCC in situ. Among case experiences that outmoded PDL and thulium lasers individually, clearance rates of 100% had been reported, whereas several case series that outmoded the CO₂ laser reported response rates that ranged from 61.5% to 100%.
• The proper evidence for clearing both BCC and SCC tumors became seen when ablative lasers similar to the CO₂ or erbium yttrium aluminum garnet are mixed with methyl aminolevulinate–photodynamic treatment (PDT) or 5-aminolevulinic acid–PDT, “likely because of the increased supply of the photosensitizing compound to neoplastic cells,” the authors wrote.

IN PRACTICE:

“Extra investigations with longer apply-up durations are vital to resolve optimal laser parameters, desire of medication sessions required, and recurrence rates (the use of whole histologic prognosis by draw of step sectioning) earlier than lasers can entirely be adopted into medical be aware,” the authors wrote. “Surgical excision, particularly Mohs micrographic surgical procedure,” they added, “persists as the gold traditional for excessive-possibility and cosmetically nonetheless tumors, offering the very most practical medicine rates in a single workplace consult with.”

SOURCE:

Amanda Rosenthal, MD, of the Department of Dermatology, Kaiser Permanente Los Angeles Clinical Center, and colleagues conducted the evaluate. The watch became published in the August topic of Dermatologic Surgery.

LIMITATIONS:

Laser treatment is not FDA-authorized for the medicine of NMSC and remains an replacement medicine possibility. Additionally, most published compare focal level on BCCs, whereas compare on cutaneous SCCs are more restricted.

DISCLOSURES:

The researchers reported having no monetary disclosures.